Dominari Holdings Inc.
https://aikidopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dominari Holdings Inc.
Tech Transfer Roundup: Santhera Exits Congenital Muscular Dystrophy Pact To Focus On DMD
Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.
New Data Boost For Intellia’s Pioneering In Vivo Gene-Editing Therapy
New data show that a high dose of Intellia’s in vivo CRISPR-Cas9 based therapy is safe and effective for up to six months, which could unlock a new era in genetic disease treatment.
Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
Tech Transfer Roundup: Trio Of Deals Bolster Spherix’s Cancer Strategy
The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Biospherics.net Incorporated
- Biospherix Ltd
- CBM BioPharma, Inc.
- Hoth Therapeutics, Inc.
- Spherix Consulting, Inc.
- Spherix Incorporated
- AIkido Pharma Inc.
- AIkido Labs, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice